

BIOSANTE PHARMACEUTICALS INC  
Form 8-K  
June 03, 2002

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**Current Report**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported):

**May 31, 2002**

**BIOSANTE PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or Other Jurisdiction of Incorporation)

**0-28637**

(Commission File Number)

**58-2301143**

(I.R.S. Employer Identification Number)

**111 Barclay Boulevard  
Lincolnshire, Illinois**

(Address of Principal Executive Offices)

**60069**

(Zip Code)

**(847) 478-0500**

(Registrant's Telephone Number, Including Area Code)

N/A

Edgar Filing: BIOSANTE PHARMACEUTICALS INC - Form 8-K

(Former Name or Former Address, If Changed Since Last Report)

---

**Item 5. Other Events**

BioSante Pharmaceuticals, Inc. reports that a press release, a copy of which is filed herewith as Exhibit 99.1, was issued on June 3, 2002. The press release announced that effective as of 5:00 p.m., Central Daylight Savings Time, on May 31, 2002, BioSante Pharmaceuticals has effected a 1-for-10 reverse split of its issued and outstanding common stock and class C special stock. In connection with the reverse split, BioSante's trading symbol changed from BTPH to BISP.

**Item 7. Financial Statements and Exhibits.**

(a) Financial Statements of Businesses Acquired.

Not Applicable

(b) Pro Forma Financial Information.

Not Applicable

(c) Exhibits.

| <u>Exhibit No.</u> | <u>Description</u> |
|--------------------|--------------------|
|--------------------|--------------------|

|          |                                                                   |
|----------|-------------------------------------------------------------------|
| Ex. 99.1 | Press Release dated June 3, 2002 (filed herewith electronically). |
|----------|-------------------------------------------------------------------|

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**BIOSANTE PHARMACEUTICALS, INC.**

By: /s/ Phillip B. Donenberg

Phillip B. Donenberg

*Chief Financial Officer, Treasurer and Secretary*

Dated: June 3, 2002

**BIOSANTE PHARMACEUTICALS, INC.**

**FORM 8-K**

**Exhibit Index**

| <b>Exhibit No.</b> | <b>Description</b>                                                  | <b>Method of Filing</b> |
|--------------------|---------------------------------------------------------------------|-------------------------|
| 99.1               | Press Release of BioSante Pharmaceuticals, Inc. issued June 3, 2002 | Filed herewith          |